- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Nilotinib
Total 33 results
-
Novartis PharmaceuticalsCompletedCML | Nilotinib | Imatinib Resistant | Imatinib IntolerantKorea, Republic of
-
Tang-Du HospitalActive, not recruitingLung Cancer | Chemotherapy | Sintilimab | AnlotinibChina
-
Tianjin Medical University Cancer Institute and...Not yet recruitingNSCLC | EGFR Activating Mutation | Anlotinib | TP53 | Aumolertinib
-
University of Maryland, BaltimoreCompletedBasic Science Study of the Mechanisms of Attentional Enhancement by Compounds Acting on the Nicotinic ReceptorUnited States
-
Peng YuanCompletedBreast Neoplasm | Antineoplastic Agents | AnlotinibChina
-
Shenzhen Second People's HospitalDongguan People's Hospital; Zhongshan People's Hospital, Guangdong, China; The... and other collaboratorsRecruitingChronic Myeloid Leukemia, Chronic Phase | NilotinibChina
-
Chinese PLA General HospitalNot yet recruitingHepatocellular Carcinoma | Anlotinib | Thermal Ablation | PDL-1China
-
Asan Medical CenterUnknownLung Cancer | ErlotinibKorea, Republic of
-
Samsung Medical CenterCompletedLung Neoplasms | Neoadjuvant Therapy | ErlotinibKorea, Republic of
-
Cancer Institute and Hospital, Chinese Academy...RecruitingAnlotinib | Sarcoma,Soft Tissue | Trunk | Extremity | Intensity-modulated Radiotherapy | Major Wound ComplicationsChina
-
The First People's Hospital of LianyungangChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownLung Neoplasms | Anlotinib | Docetaxel | S-1 | PemetrexedChina
-
Shanghai Minimally Invasive Surgery CenterWithdrawnRectal Cancer | Anlotinib | Neoadjuvant Treatment
-
Shanghai Changzheng HospitalUnknownGastric Cancer | Immunotherapy | Anlotinib | Toripalimab | Gastro-oesophageal Junction CancerChina
-
Tang-Du HospitalCompletedSintilimab and Anlotinib in Combination With ChemotherapyChina
-
Ruijin HospitalRecruitingSoft Tissue Sarcoma | Radiotherapy | Anlotinib | High Risk of RecurrenceChina
-
Shanghai Changzheng HospitalRecruitingColorectal Cancer | Immunotherapy | Sintilimab | First-line Treatment | Anlotinib | Chemo-free TherapyChina
-
Peking Union Medical College HospitalRecruitingAnlotinib | Anti-PD-1 Antibody | Advanced Pancreatic CancerChina
-
Tianjin Medical University Second HospitalNot yet recruitingUrogenital Neoplasms | Urothelial Carcinoma | Antineoplastic Agents | Gemcitabine | Cisplatin | Anlotinib | CarboplatinChina
-
Degan LuWu Jieping Medical FoundationNot yet recruitingLung Cancer | Anlotinib | TKI Resistance | EGFR Sensitive Mutation | Pianzumab
-
Shanghai Chest HospitalUnknown
-
First Affiliated Hospital Xi'an Jiaotong UniversityChia Tai Tianqing Pharmaceutical Group Co., Ltd.Active, not recruitingHepatocellular Carcinoma | Anlotinib | TACEChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Unknown
-
Wuhan Union Hospital, ChinaUnknownSmall Cell Lung Cancer | Anlotinib | Durvalumab
-
Baodong QinUnknownNSCLC Stage IV | Anlotinib | EGFR T790M-negative | JS001China
-
Xiaorong DongUnknown
-
Sichuan UniversityChia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedNon-squamous Non-small-cell Lung Cancer | AnlotinibChina
-
First People's Hospital of HangzhouRecruitingRelapsed Small Cell Lung Cancer | AnlotinibChina
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruitingTo Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer
-
Sun Yat-sen UniversityCompletedRadiotherapy | Sintilimab | Anlotinib | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | Early Stage | Peg-aspargase | Phase Two | OpenChina
-
Peking Union Medical College HospitalNot yet recruitingAnlotinib | Advanced Esophageal Squamous Cell Cancer | SHR-1210
-
Wenjun ChengNot yet recruitingNeoplasms by Histologic Type | Neoplasms by Site | Carcinoma | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Female | Endocrine System Diseases | Ovarian Diseases | Ovarian Neoplasms | Fallopian Tube Neoplasms | Carcinoma, Ovarian Epithelial | Angiogenesis | Genital Diseases, Female | Antineoplastic... and other conditions
-
Lei LiRecruitingChemotherapy | Ovarian Carcinoma | Survival Outcomes | Adverse Events | Niraparib | Anlotinib | CA125 | Targeted Therapy | Recurrent Ovarian CancerChina
-
Xiaoxiang ChenRecruitingNeoplasms | Neoplasms by Histologic Type | Urogenital Neoplasms | Neoplasms by Site | Carcinoma | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Female | Ovarian Diseases | Adnexal Diseases | Carcinoma, Ovarian Epithelial | Ovarian Cancer | Angiogenesis | Genital Diseases, Female | Antineoplastic Agents | BRCA1... and other conditionsChina